SecBot SecBot

ACHV

ACHIEVE LIFE SCIENCES, INC.
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0000949858 Biotech & Drug Discovery
$6.49 −0.01 (−0.15%)
Oct 23 4:00 PM ET · prev $6.50
Market cap
$668.9M
Small cap
Consensus
Buy
94% Buy or better · 18 analysts
Median target
🔒 Subscribers only
1 year
+29.8%
from $5.00 · Oct 24
30 days
−17.1%
from $7.83
52-week range
$2.65–8.53
−24% from high · low Mar 27
Avg volume 20D
1.40M
shares / day
Short interest
17.47M
≈17.0% of shares · +9.3%
Days to cover
10.9
at average volume
Insider net
-$175.2K
0 buyers · 1 seller · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/6 ·Next Earnings date, Nov 5, 2026
Strongest BEARISH Achieve Life Sciences reported Q2 2026 EPS of -$0.80, significantly missing the consensus estimate of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $175.2K.

  • InstitutionsBULLISH

    Q2 2026: 22 added (1 new), 6 trimmed or exited. Largest new: Alyeska Investment Group, $12.6M.

  • AnalystsBULLISH

    17 of 18 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +9.3% to 17.47M shares. 10.9 days to cover, ≈17.0% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.6M
in new stakes
FundMoveSharesValue
BlackRock, Inc.DOUBLED5,272,017$34.4M
VANGUARD CAPITAL MANAGEMENT LLCADD4,140,812$27.0M
MARSHALL WACE, LLPDOUBLED3,770,313$24.6M
STATE STREET CORPDOUBLED2,945,526$19.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED2,062,721$13.5M
Alyeska Investment Group, L.P.NEW1,925,722$12.6M
NORTHERN TRUST CORPDOUBLED743,760$4.9M
VANGUARD FIDUCIARY TRUST COADD593,751$3.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 94% rate it Buy or better
Strong Buy4Buy13Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 30, 2026Stifel
INITIATE
INITIATEBuy
Aug 13, 2026Morgan Stanley
INITIATE
INITIATEOverweight
Jun 22, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$175.2K
sold · 1 insider
DateInsiderTypeValue
Oct 5, 2026
Halladay Benjamin
Chief Financial Officer
AWARD200,000 sh
Oct 5, 2026
Halladay Benjamin
Chief Financial Officer
AWARD200,000 sh
Aug 19, 2026
Stewart Richard Alistair
Director
SELL$175.2K
Jul 27, 2026
Sellig Thomas
Director
AWARD16,700 sh
Jul 27, 2026
Sellig Thomas
Director
AWARD25,000 sh
Jul 27, 2026
Farrow Jeffrey S
Director
AWARD16,700 sh
Jul 27, 2026
Farrow Jeffrey S
Director
AWARD25,000 sh
Jul 27, 2026
Stewart Richard Alistair
Director
AWARD25,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
17,474,108
shares short
+9.3%
vs prior settlement
10.9
days to cover
≈17.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Benjamin Halladay filed a Form 3 initial statement of beneficial ownership upon becoming Chief Financial Officer of…
3 — Impact 2/10
Oct 5, 2026 Insider
Halladay Benjamin was granted 200,000 shares
Chief Financial Officer
Oct 5, 2026 Insider
Halladay Benjamin was granted 200,000 shares
Chief Financial Officer
Oct 1, 2026 SEC
Achieve Life Sciences announced the appointment of Benjamin Halladay as CFO, effective October 5, 2026, replacing Mark…
8-K — Impact 3/10
Oct 1, 2026 Other
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Brings public company CFO experience across commercial pharma and business development as Achieve pr
Aug 19, 2026 Insider
Stewart Richard Alistair sold 20,626 shares
Director @ $8.49 ($175.2K)
Aug 14, 2026 SEC
Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market…
8-K — Impact 5/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
5,272,017 shares ($34.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 1, 2026
Press release
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of…
Sep 30, 2026
Short interest
Short Interest: ACHV up 9% to 17.5M shares
Settlement 2026-09-30 | Days to cover: 10.88 | ≈16.98% of shares outstanding (est.)
Sep 28, 2026
Press release
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty…
Sep 3, 2026
Press release
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty…
Aug 11, 2026
Earnings
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20…

SecBot reports

12 filings · 4 press releases · 1 bullish · 5 bearish · 2 mixed · 4 neutral
All ACHV filing & press-release reports (16)